HPV-associated diseases, such as cervical and other anogenital cancers, cervical and anal
intraepithelial neoplasia, genital warts, and recurrent respiratory papillomatosis confer …

Prophylactic HPV vaccination has been a great public health success. For> 20 years, clinical
trials were conducted with the 2-, 4-, and/or 9-valent vaccines in young-adult females, mid …

Human papillomavirus (HPV) is the necessary cause of cervical cancer, the fourth most
common cancer and cause of cancer-related death in females worldwide. HPV also causes …

When HPV vaccines were registered in 2006/2007, it was unclear whether these new and
type-specific prophylactic vaccines would be accepted by the community for cancer …

Routine vaccination programs have had a substantial impact on reducing the prevalence of
a variety of infectious diseases. In light of the fact that human papillomavirus (HPV) is a …

Human papillomavirus (HPV), a sexually transmitted infection and the etiologic cause of
genital warts and cervical cancer, is highly prevalent in sexually active men and women …

Human Papillomavirus (HPV) infection causes cervical cancer, a significant portion of anal,
vulvar, vaginal, and oropharyngeal cancers, genital warts, and recurrent respiratory …

Human papillomavirus (HPV) is the most common sexually transmitted infection in the
United States, and persistent HPV infection is strongly associated with risk of cervical cancer …

Early data from randomized controlled trials consistently show that prophylactic human
papillomavirus virus-like particle (HPV VLP) vaccines are effective in preventing infection …

New prophylactic HPV vaccines have the power to prevent many HPV infections, thus
reducing the burden of HPV-associated diseases. Two vaccines composed of HPV L1 …